Science
BlossomHill is rationally designing and developing medicines to overcome some of the toughest challenges in cancer and autoimmune treatment.
Despite significant advances in cancer therapy and precision medicine, cures remain elusive due to cancer’s remarkable ability to develop tolerance and resistance to treatments, one of the toughest and most important problems to solve for patients.
Cancer’s resistance comes in two primary forms:
On-Target Resistance
Cancer cells mutate the very targets that drugs aim to attack, rendering the drugs less effective.
OFF-Target Resistance
Cancer evolves to bypass the pathway involved in a treatment by activating alternative signaling pathways as a way to survive.
To outpace cancer’s adaptability, BlossomHill aims to develop treatments that consider the full spectrum of its survival mechanisms.
By creating drugs that can counteract both known and potential future resistance mechanisms, we can offer more durable and effective therapies, bringing us closer to turning cancer from a terminal illness into a manageable condition.